secwatch.observer — SEC 8-K summary
======================================

Issuer:     Beyond Air, Inc. (XAIR)
CIK:        0001641631
Form:       8-K
Filed at:   2025-09-08T23:59:59+00:00
Accession:  0001493152-25-012825
Event type: regulatory
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NeuroNOS (Beyond Air unit) receives FDA Orphan Drug Designation for BA-101 in glioblastoma
--------------------------------------------------------------------------------

- FDA grants Orphan Drug Designation for BA-101, an investigational nNOS inhibitor, for treatment of glioblastoma.
- This is NeuroNOS's second orphan drug designation; ODD provides tax credits, fee waivers, and 7-year market exclusivity if approved.
- GBM median survival is <12 months; standard of care (surgery, radiation, temozolomide) is not curative.
- NeuroNOS CEO cites urgent unmet need and NO modulation strategy; preclinical data showed NOS inhibition reduced GBM cell proliferation.
- Company plans to advance BA-101 toward first-in-human studies.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1641631/000149315225012825/0001493152-25-012825-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1641631/000149315225012825/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-012825

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer